Esperion Therapeutics (NASDAQ:ESPR) Upgraded to “Buy” at Wall Street Zen

Esperion Therapeutics (NASDAQ:ESPR) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday.

Other equities analysts have also recently issued reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Esperion Therapeutics in a research report on Thursday, January 22nd. Citizens Jmp raised their target price on Esperion Therapeutics from $4.00 to $5.00 and gave the stock a “market outperform” rating in a research report on Friday. Piper Sandler initiated coverage on Esperion Therapeutics in a research note on Tuesday, November 25th. They issued an “overweight” rating and a $9.00 price target for the company. Needham & Company LLC lifted their price objective on Esperion Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a research note on Tuesday, March 3rd. Finally, HC Wainwright reissued a “buy” rating on shares of Esperion Therapeutics in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $7.60.

Esperion Therapeutics Stock Performance

Shares of NASDAQ:ESPR opened at $2.44 on Friday. Esperion Therapeutics has a 52-week low of $0.69 and a 52-week high of $4.18. The company has a market capitalization of $626.62 million, a PE ratio of -14.35, a price-to-earnings-growth ratio of 1.18 and a beta of 1.11. The company has a fifty day moving average of $3.28 and a 200-day moving average of $3.14.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Tuesday, March 10th. The biopharmaceutical company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.23 by ($0.01). The business had revenue of $168.45 million during the quarter, compared to analysts’ expectations of $165.12 million. On average, equities analysts forecast that Esperion Therapeutics will post -0.29 EPS for the current fiscal year.

Insider Buying and Selling

In other Esperion Therapeutics news, CFO Benjamin Halladay sold 7,337 shares of Esperion Therapeutics stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $3.67, for a total value of $26,926.79. Following the completion of the sale, the chief financial officer directly owned 467,525 shares of the company’s stock, valued at approximately $1,715,816.75. The trade was a 1.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold 15,543 shares of company stock valued at $55,709 in the last ninety days. Company insiders own 1.70% of the company’s stock.

Hedge Funds Weigh In On Esperion Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. AIGH Capital Management LLC acquired a new position in shares of Esperion Therapeutics during the third quarter worth approximately $7,950,000. Two Seas Capital LP grew its position in Esperion Therapeutics by 43.6% in the 2nd quarter. Two Seas Capital LP now owns 9,954,975 shares of the biopharmaceutical company’s stock valued at $9,800,000 after purchasing an additional 3,024,104 shares during the period. Royce & Associates LP acquired a new stake in Esperion Therapeutics in the 3rd quarter valued at $6,078,000. Diametric Capital LP increased its stake in Esperion Therapeutics by 57.8% during the 2nd quarter. Diametric Capital LP now owns 678,824 shares of the biopharmaceutical company’s stock valued at $668,000 after purchasing an additional 248,648 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new position in Esperion Therapeutics during the third quarter worth $476,000. Institutional investors own 47.39% of the company’s stock.

Trending Headlines about Esperion Therapeutics

Here are the key news stories impacting Esperion Therapeutics this week:

• Positive Sentiment: Citizens Jmp raised its price target on ESPR to $5.00 (from $4.00) and assigned a “market outperform” rating — implying roughly 105% upside vs. the reference $2.44 level, which could attract buyers and trigger short‑covering. Article Title Article Title
• Neutral Sentiment: Street analysts published Q4 forecasts for ESPR; these refreshes create short‑term volatility but are routine ahead of reporting periods — watch actual Q4 results vs. the new consensus for a catalyst. Article Title
• Negative Sentiment: HC Wainwright lowered multi‑year EPS targets materially while maintaining a “Buy” rating: FY2026 cut to $0.00 (from $0.58), FY2027 to $0.25 (from $0.81) and FY2028 to $0.45 (from $1.07). The firm also models small quarterly losses (Q1 -$0.08, Q2 -$0.05, Q3 -$0.04) before the projected recovery — the revisions reduce future earnings power embedded in current valuations and likely weigh on the stock. Article Title

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.